Effects of food and drug administration warnings on antidepressant use in a national sample

Archives of General Psychiatry

Volumn 65, Issue 1, 2008, Pages 94-101

  Olfson, Mark ^a   Marcus, Steven C ^b   Druss, Benjamin G ^c  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; AMOXAPINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DOXEPIN; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; ISOCARBOXAZID; MAPROTILINE; MIRTAZAPINE; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; PHENELZINE; PROTRIPTYLINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; VENLAFAXINE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CONTROLLED STUDY; DRUG INFORMATION; DRUG USE; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; INFORMATION DISSEMINATION; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; OUTCOME ASSESSMENT; PATIENT CODING; PHARMACY; PRESCRIPTION; SAMPLING; SEX DIFFERENCE; TIME SERIES ANALYSIS; TREATMENT CONTRAINDICATION; ADOLESCENT; AGE; CHILD; CLINICAL PRACTICE; DRUG LABELING; HEALTH SURVEY; MIDDLE AGED; STATISTICS; SUICIDE ATTEMPT; UNITED STATES;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTIDEPRESSIVE AGENTS; CHILD; DRUG LABELING; FEMALE; HEALTH SURVEYS; HUMANS; MALE; MIDDLE AGED; PAROXETINE; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS, DRUG; SEX FACTORS; SUICIDE, ATTEMPTED; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 38049169579     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archgenpsychiatry.2007.5     Document Type: Article

References (46)

1. Jacoby JL, Fulton J, Cesta M, Heller M. After the black box warning: dramatic changes in ED use of droperidol. Am J Emerg Med. 2005;23(2):196.
2. Weatherby LB, Walker AM, Fife D, Vervaet P, Klausner MA. Contraindicated medications dispensed with cisapride: temporal trends in relation to the sending of "dear doctor" letters. Pharmacoepidemiol Drug Saf. 2001;10(3):211-218.
3. Soumerai SB, Avorn J, Gortmaker S, Hawley S. Effect of government and commercial warnings on reducing prescription misuse: the case of propoxyphene. Am J Public Health. 1987;77(12):1518-1523.
4. Rosack J. New data show declines in antidepressant prescribing. Psychiatr News. 2005;40(17):1-3.
5. Nemeroff CB, Kalali A, Keller MB, Charney DS, Lenderts SE, Cascade EF, Stephenson H, Schatzberg F. Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States. Arch Gen Psychiatry. 2007;64(4):466-472.
6. Teicher MH, Gold C, Cole JO. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry. 1990;147(2):207-210.
7. King RA, Riddle MA, Chappell PB, Hardin MT, Anderson GM, Lombroso P, Scahill L. Emergence of self-destructive phenomena in children and adolescents during fluoxetine treatment. J Am Acad Child Adolesc Psychiatry. 1991;30(2):179-186.
8. Masand P, Gupta S, Deewan M. Suicide ideation related to fluoxetine treatment. N Engl J Med. 1991;324(6):420.
9. Rothschild AJ, Locke CA. Reexposure to fluoxetine after serious suicide attempts by three patients: the role of akathisia. J Clin Psychiatry. 1991;52(12):491-493.
10. Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry. 2006;63(3):332-339.
11. Selective serotonin reuptake inhibitors (SSRIs): overview of regulatory status and CSM advice relating to major depressive disorder (MDD) in children and adolescents including a summary of available and efficacy data. Medicines and Healthcare Products Regulation Agency Web site. http://www.mhra.gov.uk/home/ idcplg?IdcService=SS_GET_PAGE&useSecondary=true&ssDocName= CON019494&ssTargetNodeId=221. Accessed June 20, 2006.
12. Fergusson D, Doucette S, Glass K, Shapiro S, Healy D, Hebert P, Hutton B. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomized controlled trials. BMJ. 2005;330(7488):396-399.
13. Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomized trials submitted to the MHRA's safety review. BMJ. 2005;330(7488):385-388.
14. Laughren TP. Overview for December 13 Meeting of Psychopharmacology Drugs Advisory Committee. http://www.fda.gov/OHRMS/DOCKETS/AC/06/briefing/2006- 4272b1-01-FDA.pdf. Accessed May 11, 2007.
15. March J, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, Burns B, Domino M, McNulty S, Vitiello B, Severe J. Treatment for Adolescents With Depression Study (TADS) Team: fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression. Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA. 2004;292(7):807-820.
16. Geddes JR, Carney SM, Davies C, Furukawa TA, Kupfer DJ, Frank E, Goodwin GM. Relapse prevention with antidepressant drug treatment in depressive disorders. Lancet. 2003;361(9358):653-661.
17. Conwell Y, Duberstein PR, Cox C, Hermann JH, Forbes NT, Caine ED. Relationships of age and axis I diagnoses in victims of completed suicide: a psychological autopsy. Am J Psychiatry. 1996;153(8):1001-1008.
18. Foster T, Gillespie K, McClelland R. Mental disorders and suicide in Northern Ireland. Br J Psychiatry. 1997;170:447-452.
19. Shaffer D, Gould MS, Fisher P, Trautman P, Moreau D, Kleinman M, Flory M. Psychiatric diagnosis in child and adolescent suicide. Arch Gen Psychiatry. 1996;53(4):339-348.
20. Brent DA, Perper J, Moritz G, Allman C, Friend A, Roth C, Schweers J, Balach L, Baugher M. Psychiatric risk factors for adolescent suicide: a case-control study. J Am Acad Child Adolesc Psychiatry. 1993;32(3):521-519.
21. FDA talk paper: FDA statement regarding the anti-depressant Paxil for pediatric population. US Food and Drug Administration Web site. http://www.fda.gov/bbs/topics/ANSWERS/2003/ANS01230.html. Published June 19, 2003. Accessed July 31, 2004.
22. FDA public health advisory: worsening depression and suicidality in patients being treated with antidepressant. US Food and Drug Administration Web site. http://www.fda.gov/cder/drug/antidepressants/AntidepressanstPHA.htm. Published March 22, 2004. Accessed March 17, 2005.
23. FDA public health advisory: suicidality in children and adolescents being treated with antidepressant medications. US Food and Drug Administration Web site. http://www.fda.gov/CDER/DRUG/antidepressants/SSRIPHA200410.htm. Published October 15, 2004. Accessed December 20, 2004.
24. Harris G. FDA toughens warning on antidepressant drugs. New York Times. October 16, 2004. http://www.nytimes.com/2004/10/16/politics/ 16depress.html. Accessed December 20, 2004.
25. Vedantam S. Depression drugs to carry warning: FDA orders notice of risks for youths. Washington Post. October 16, 2004:A01.
26. Brent DA. Antidepressants and pediatric depression - the risk of doing nothing. N Engl J Med. 2004;351(16):1598-1601.
27. Newman TB. A black-box warning for antidepressants in children? N Engl J Med. 2004;351(16):1595-1598.
28. Shea JA, Kletke PR, Wozniak GD, Polsky D, Escarce JJ. Self-reported physician specialties and the primary care content of medical practice: a study of the AMA physician masterfile. Med Care. 1999;37(4):333-338.
29. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan DR. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002;27(4):299-309.
30. Marshall RD, Posner K, Greenhill L. Risk perception research and the black box warning for SSRIs in children. J Am Acad Child Adolesc Psychiatry. 2006;45(7):765.
31. Lineberry TW, Bostwick JM, Beebe TJ, Decker PA. Impact of the FDA black box warning on physician antidepressant prescribing and practice patterns: opening Pandora's suicide box. Mayo Clin Proc. 2007;82(4):518-520.
32. Bennett K, Teeling M, Feely J. Overprescribing antidepressants to children: pharmacoepidemiological study in primary care. BMJ. 2005;331(7530):1451-1452.
33. Irish Medicines Board. Statement on Behalf of the Irish Medicine Board on Selective Serotonin Reuptake Inhibitors. Dublin, Ireland: Irish Medicines Board; 2003.
34. Kurdyak PA, Juurlink DN, Mamdani MM. The effect of antidepressant warnings on prescribing trends in Ontario, Canada. Am J Public Health. 2007;97(4):750-754.
35. Wild J. Adult suicides linked to popular antidepressant. Nature. 2005;436(7054):1073.
36. Nutt DJ. Overview of diagnosis and drug treatments of anxiety disorders. CNS Spectr. 2005;10(1):49-56.
37. Jureidini JN, Doecke CJ, Mansfiedl PR, Haby MM, Menkes DB, Tonkin AL. Efficacy and safety of antidepressants for children and adolescents. BMJ. 2004;328(7444):879-883.
38. Bridge JA, Iyengar S, Salary CB, Barbe RP, Birmaher B, Pincus HA, Ren L, Brent DA. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA. 2007;297(15):1683-1695.
39. Brent DA, Baugher M, Bridge J, Chen T, Chiappetta L. Age- and sex-related risk factors for adolescent suicide. J Am Acad Child Adolesc Psychiatry. 1999;38(12):1497-1505.
40. Spicer RS, Miller TR. Suicide acts in 8 states: incidence and case fatality rates by demographics and method. Am J Public Health. 2000;90(12):1885-1891.
41. FDA medication guide about using antidepressants in children and teenagers. http://www.fda.gov/cder/drug/antidepressants/mg_template.pdf. Revised January 26, 2005. Accessed March 1, 2005.
42. Miller P, Chilvers C, Dewey M, Fielding K, Gretton V, Palmer B, Weller D, Churchill R, Williams I, Bedi N, Duggan C, Lee A, Harrison G. Counseling versus antidepressant therapy for the treatment of mild to moderate depression in primary care; economic analysis. Int J Technol Assess Health Care. 2003;19(1):80-90.
43. Melfi CA, Croghan TW, Hanna MP. Access to treatment for depression in a Medicaid population. J Health Care Poor Underserved. 1999;10(2):201-215.
44. Olfson M, Marcus SC, Tedeschi M, Wan GJ. Continuity of antidepressant treatment for adult depression in the United States. Am J Psychiatry. 2006;163(1):101-108.
45. Harman JS, Edlund MJ, Fortney JC. Disparities in the adequacy of depression treatment in the United States. Psychiatr Serv. 2004;55(12):1379-1385.
46. Grunebaum MF, Ellis SP, Li S, Oquendo MA, Mann JJ. Antidepressants and suicide risk in the United States. J Clin Psychiatry. 2004;65(11):1456-1462.